NCT07164469

Phase 2 Trial of CD70.CAR NK Cells for Patients With Primary Refractory or Early Relapsed Diffuse Large B-Cell Lymphoma and Hodgkin Lymphoma

• Status: Not Yet Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 100 (estimated)
• Sponsor: M.D. Anderson Cancer Center · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This clinical research study is to learn if CD70.CAR NK cell therapy can help to control early relapsed or primary refractory DLBCL and cHL.

Detailed description

Primary Objective: The primary objective of the study is to determine the efficacy of CB-derived CD70.CAR NK cell therapy in patients with primary refractory or early relapsed DLBCL and HL, as determined by the 2-year event-free survival rate. Secondary Objectives: * To determine the antitumor activity pf CB-derived CD70.CAR NK cells, as determined by the response rate (ORR) and complete response (CR) rate. * To establish the safety of this treatment. * To quantify the persistence of infused CB-derived CD70.CAR NK cells in the peripheral blood. * To conduct comprehensive immune studies by evaluating tissue and blood-based biomarkers associated with response and resistance to CD70.CAR NK cells.

Conditions

• Large B-cell Lymphoma
• Hodgkin Lymphoma

Interventions

Type	Name	Description
DRUG	Fludarabine	Given by IV
DRUG	Cyclophosphamide	Given by IV
DRUG	CD70.CAR NK Cells	Given by IV Infusion
DRUG	Rimiducid (AP1903)	Given by IV Infusion

Timeline

• Start date: 2026-02-28
• Primary completion: 2031-09-30
• Completion: 2033-09-30
• First posted: 2025-09-10
• Last updated: 2026-03-11

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study